Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination

Safary, Azam; Esalatmanesh, Kamal; Eftekharsadat, Amir Taher; Nakjovani, Mohammadreza Jafari; Khabbazi, Alireza

doi:10.1016/j.intimp.2022.109061

Cited by 29 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by the presence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) that cause inflammation [ 86 ]. Seven cases of de novo RA following COVID-19 vaccination have been reported, with a higher incidence in women (4/7, 57%) [ 14 , [87] , [88] , [89] , [90] , [91] ]. Four of these were reported after the mRNA vaccine and one after the Viral vector vaccine.…”

Section: Resultsmentioning

confidence: 99%

“…Although vaccination against COVID-19 has proven to be effective in reducing disease severity and mortality, some people are hesitant to get vaccinated due to concerns about side effects [ 12 ]. Recently, reports have emerged suggesting that COVID-19 vaccines may cause rare autoimmune diseases, including autoimmune glomerulonephritis [ 13 ], autoimmune rheumatic diseases [ 14 ], and autoimmune hepatitis [ 15 ]. These adverse events have increased public skepticism about vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Insights into new-onset autoimmune diseases after COVID-19 vaccination

Guo

Liu

Chen

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Insights into new-onset autoimmune diseases after COVID-19 vaccination

Guo

Liu

Chen

et al. 2023

Autoimmunity Reviews

View full text Add to dashboard Cite

“…The demographics, socioeconomic statuses, lifestyle factors, and comorbidity profiles of the study population were obtained from the NHIS database. We set covariates that may potentially be associated with the disease outcome on the basis of previous literature and the biological plausibility of associations . The predefined covariates are listed in the eMethods in Supplement 1.…”

Section: Methodsmentioning

confidence: 99%

Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Lim,

Ju,

Han

et al. 2023

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceMultiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified.ObjectiveTo investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19.Design, Setting, and ParticipantsThis was a retrospective population-based study conducted between October 8, 2020, and December 31, 2021, that used nationwide data from the Korea Disease Control and Prevention Agency COVID-19 National Health Insurance Service cohort and included individuals who received a diagnosis of COVID-19 via polymerase chain reaction testing and a control group with no evidence of COVID-19 identified from National Health Insurance Service of Korea cohort. Data analysis was conducted from September 2022 to August 2023.ExposuresReceipt of diagnosis of COVID-19.Main Outcomes and MeasuresThe primary outcomes were the incidence and risk of autoimmune and autoinflammatory connective tissue disorders following COVID-19. A total of 32 covariates, including demographics, socioeconomic statuses, lifestyle factors, and comorbidity profiles, were balanced through inverse probability weighting. The incidences and risks of autoimmune and autoinflammatory connective tissue disorders were compared between the groups using multivariable Cox proportional hazard analyses.ResultsA total of 354 527 individuals with COVID-19 (mean [SD] age, 52.24 [15.55] years; 179 041 women [50.50%]) and 6 134 940 controls (mean [SD] age, 52.05 [15.63] years; 3 074 573 women [50.12%]) were included. The risks of alopecia areata (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.05-1.19), alopecia totalis (aHR, 1.74; 95% CI, 1.39-2.17), antineutrophil cytoplasmic antibody–associated vasculitis (aHR, 2.76; 95% CI, 1.64-4.65), Crohn disease (aHR, 1.68; 95% CI, 1.31-2.15), and sarcoidosis (aHR, 1.59; 95% CI, 1.00-2.52) were higher in the COVID-19 group. The risks of alopecia totalis, psoriasis, vitiligo, vasculitis, Crohn disease, ulcerative colitis, rheumatoid arthritis, adult-onset Still disease, Sjögren syndrome, ankylosing spondylitis, and sarcoidosis were associated with the severity of COVID-19.Conclusions and RelevanceIn this retrospective cohort study, COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders, indicating that long-term management of patients with COVID-19 should include evaluation for such disorders.

show abstract

“…1 There are many reports of autoimmune disorders such as inflammatory arthritis, vasculitis, Guillain-Barre syndrome, and multiple sclerosis after vaccination against tetanus, rubella, hepatitis B, influenza, and COVID-19. 2,3 Here, we report a case of EGPA in a middle-aged man after receiving the influenza vaccine.…”

Section: Introductionmentioning

confidence: 90%

Eosinophilic granulomatosis with polyangiitis following flu guard influenza vaccination: A case report

Jafarpour,

Daneshvar,

Eftekharsadat

et al. 2023

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

Key Clinical MessageThis case highlights a potential association between influenza vaccination and the development of eosinophilic granulomatosis with polyangiitis (EGPA), prompting the need for increased vigilance regarding vaccine‐related autoimmune reactions. While causality remains unclear, clinicians should consider this possibility in patients presenting with EGPA‐like symptoms shortly after vaccination.AbstractEosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by tissue infiltration by eosinophils and hyper eosinophilia. We present a case of EGPA in a middle‐aged man following influenza vaccination. The patient developed respiratory symptoms, skin lesions, joint pain, and neurological deficits. Diagnostic tests revealed eosinophilia, positive anti‐neutrophil cytoplasmic antibodies, and elevated acute phase reactants. This report highlights a potential association between influenza vaccination and EGPA.

show abstract

Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination

Cited by 29 publications

References 35 publications

Insights into new-onset autoimmune diseases after COVID-19 vaccination

Insights into new-onset autoimmune diseases after COVID-19 vaccination

Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19

Eosinophilic granulomatosis with polyangiitis following flu guard influenza vaccination: A case report

Contact Info

Product

Resources

About